The present study was designed to characterize transduction of non-human primate brain
and spinal cord with a modified adeno-associated virus serotype 2, incapable of binding to …

The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain
barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery …

Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9)
to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that …

Adeno-associated viral vectors (AAVs) have demonstrated potential in applications for
neurologic disorders, and the discovery that some AAVs can cross the blood-brain barrier …

Gene therapy for the central nervous system is poised to become a powerful treatment for
numerous neurological disorders. Adeno-associated viral vectors based on serotype 9 …

Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood–
brain barrier via intravascular administration, making it a good candidate for diffuse gene …

Systemic and intracerebrospinal fluid delivery of adeno-associated virus serotype 9 (AAV9)
has been shown to achieve widespread gene delivery to the central nervous system (CNS) …

Recombinant adeno‐associated virus (AAV) vectors are powerful tools for both basic
neuroscience experiments and clinical gene therapies for neurological diseases …

Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic
gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery …

Adeno-associated virus serotype 9 (AAV9) has shown remarkable efficiency in transducing
organs in vivo including the heart, liver, and brain. 1–6 Recently, AAV9 has gained renewed …